Henlius Kicks Off Denosumab Trial
Chinese Firm Doses First Patient In Phase I Trial For Xgeva/Prolia Biosimilar
Shanghai Henlius Biotech has begun dosing in a Phase I trial for its HLX14 planned biosimilar version of denosumab. Multiple biosimilar developers are vying to take a slice of the market for rivals to Amgen’s Xgeva/Prolia original.
